Hsbc Holdings PLC Has $58.85 Million Holdings in IQVIA Holdings Inc. $IQV

Hsbc Holdings PLC grew its holdings in shares of IQVIA Holdings Inc. (NYSE:IQV) by 1.9% during the first quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 344,929 shares of the medical research company’s stock after purchasing an additional 6,589 shares during the period. Hsbc Holdings PLC’s holdings in IQVIA were worth $58,852,000 at the end of the most recent quarter.

Other hedge funds also recently made changes to their positions in the company. J. Safra Sarasin Holding AG lifted its position in shares of IQVIA by 174.3% during the 4th quarter. J. Safra Sarasin Holding AG now owns 12,827 shares of the medical research company’s stock valued at $2,891,000 after acquiring an additional 8,151 shares during the period. CWM LLC increased its position in shares of IQVIA by 23.9% in the fourth quarter. CWM LLC now owns 55,830 shares of the medical research company’s stock worth $12,585,000 after purchasing an additional 10,762 shares during the period. Franklin Street Advisors Inc. NC acquired a new position in IQVIA in the fourth quarter valued at about $15,724,000. Calamos Advisors LLC lifted its position in IQVIA by 268.1% during the fourth quarter. Calamos Advisors LLC now owns 188,707 shares of the medical research company’s stock worth $42,536,000 after purchasing an additional 137,441 shares during the period. Finally, HF Advisory Group LLC lifted its position in IQVIA by 1,791.6% during the fourth quarter. HF Advisory Group LLC now owns 154,618 shares of the medical research company’s stock worth $34,852,000 after purchasing an additional 146,444 shares during the period. 89.62% of the stock is owned by institutional investors.

IQVIA Stock Performance

Shares of IQVIA stock opened at $206.26 on Monday. The firm’s 50 day moving average is $185.04 and its 200 day moving average is $187.88. The firm has a market capitalization of $34.42 billion, a PE ratio of 25.56, a price-to-earnings-growth ratio of 1.85 and a beta of 1.20. IQVIA Holdings Inc. has a 1 year low of $154.50 and a 1 year high of $247.04. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 2.20.

IQVIA (NYSE:IQV) last issued its quarterly earnings data on Tuesday, May 5th. The medical research company reported $2.90 EPS for the quarter, beating the consensus estimate of $2.83 by $0.07. The business had revenue of $4.15 billion during the quarter, compared to the consensus estimate of $4.10 billion. IQVIA had a net margin of 8.33% and a return on equity of 30.50%. The firm’s revenue was up 8.4% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $2.70 EPS. IQVIA has set its FY 2026 guidance at 12.650-12.950 EPS. Equities research analysts forecast that IQVIA Holdings Inc. will post 11.57 earnings per share for the current fiscal year.

IQVIA declared that its Board of Directors has initiated a share repurchase program on Thursday, May 7th that permits the company to repurchase $2.00 billion in shares. This repurchase authorization permits the medical research company to reacquire up to 6.8% of its shares through open market purchases. Shares repurchase programs are generally an indication that the company’s leadership believes its shares are undervalued.

Analysts Set New Price Targets

Several research firms have commented on IQV. Mizuho raised their target price on shares of IQVIA from $215.00 to $230.00 and gave the company an “outperform” rating in a report on Monday, July 13th. Wall Street Zen downgraded shares of IQVIA from a “buy” rating to a “hold” rating in a report on Saturday, June 27th. Deutsche Bank Aktiengesellschaft set a $240.00 price objective on shares of IQVIA in a research note on Thursday, July 9th. HSBC restated a “buy” rating and set a $240.00 price objective on shares of IQVIA in a research report on Monday, July 6th. Finally, Robert W. Baird raised their target price on IQVIA from $230.00 to $249.00 and gave the company an “outperform” rating in a report on Wednesday, July 1st. Fourteen equities research analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $225.71.

About IQVIA

IQVIA (NYSE: IQV) is a global provider of advanced analytics, technology solutions and contract research services to the life sciences industry. The company combines clinical research capabilities with large-scale health data and analytics to support drug development, regulatory reporting, commercial strategy and real?world evidence generation. IQVIA traces its current form to the combination of Quintiles and IMS Health announced in 2016 and subsequently rebranded as IQVIA, bringing together long-established clinical research operations and extensive healthcare information assets.

IQVIA’s principal activities include outsourced clinical development services (acting as a contract research organization for phases I–IV), real?world evidence and observational research, regulatory and safety services, and a suite of technology platforms that enable data integration, analytics and operational management.